EMA Authorised: Inductos (dibotermin alfa) — Medtronic BioPharma B.V.

View source ↗

Summary

EMA authorises Inductos (dibotermin alfa) for tibial fractures, fracture fixation internal, and spinal fusion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fracture Fixation
• Spinal Fusion
• Tibial Fracture

Drugs mentioned

• InductOs (bone morphogenetic protein-2 (rhBMP-2))

Snippet

Status: Authorised. Therapeutic area: Tibial Fractures;Fracture Fixation, Internal;Spinal Fusion. MAH: Medtronic BioPharma B.V.. Decision date: 02/09/2021